Here’s a thing about extracellular vesicle (EV) therapeutics that doesn’t get talked about enough: the science is promising, but nobody can make them at scale. Current EV production processes are plagued by low yields, high costs, and a stubborn refusal to behave predictably in bioreactors. It’s a manufacturing problem masquerading as a science problem — and ARPA-H just put $18.3 million behind the idea that fixing it could unlock the entire modality.
Landmark Bio, an Artis BioSolutions company, just received the award to build what they’re calling the TRANSFORM EV project — a scalable, continuous manufacturing platform for EV therapeutics. This isn’t tied to any single drug or indication. It’s infrastructure. Plumbing. The unsexy stuff that makes everything else possible.
And that’s exactly why it matters.
The Biotech Voyager
Early-stage biotech signals, personalized.
The signals that matter to you — contextualized and written directly to you — so you cut through the noise and immediately understand why it matters.
If you follow the advanced therapy CDMO space, you know Landmark Bio. Based in Watertown, Massachusetts, they were acquired by Artis BioSolutions in 2025 and specialize in cell therapy, viral vector, RNA, and nanoparticle manufacturing. They already serve academic institutions and biopharma companies building next-generation genetic medicines. Adding EV manufacturing to that platform is a logical — and potentially lucrative — expansion.
ARPA-H, for those keeping score at home, is the Advanced Research Projects Agency for Health — the government’s high-risk, high-reward health research arm modeled after DARPA. They don’t fund incremental improvements. They fund moonshots. And the bet here is clear: EVs could be a transformative therapeutic modality, but they’ll never get there if manufacturing remains artisanal.
The TRANSFORM EV project aims to build continuous production processes that can be standardized and scaled — the kind of platform that could serve dozens of EV therapy developers simultaneously. Think of it as building the highway before the cars are ready. If it works, Landmark Bio becomes the go-to manufacturing partner for an entire emerging modality. That’s a strategic position worth far more than $18.3 million.
